How much revenue does Statera Biopharma make?

Statera Biopharma reported $0 in revenue for fiscal year 2021. In Q3 2022 revenue was $0.

What companies are similar to Statera Biopharma?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include 0913693 B.c. Ltd. (REPCF), Gelesis Holdings, Inc. (GLSHQ), SES Solar Inc. (SESI), FluoroPharma Medical, Inc. (FPMI).

Statera Biopharma, Inc. (STAB) Stock

About Statera Biopharma, Inc.

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and...

At a glance

Statera Biopharma reported revenue of $0 for fiscal year 2021, and net income of -$101.85 million. In Q3 2022 (the quarter ended September 30, 2022) revenue was $0.

Figures from company filings; latest fiscal year ended December 31, 2021.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.